Genomics and pharmacogenomics of pancreatic adenocarcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Link
http://www.nature.com/articles/tpj201152.pdf
Reference82 articles.
1. Burris III H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.
2. Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960–1966.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N Eng J Med 2011; 364: 1817–1825.
4. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002; 94: 902–910.
5. Cunningham D, Chau I, Stocken D, Valle J, Smith D, Steward W et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513–5518.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1;Pancreas;2018-05
2. Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review;Critical Reviews™ in Therapeutic Drug Carrier Systems;2018
3. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients;PLOS ONE;2017-12-07
4. Molecular alterations contributing to pancreatic cancer chemoresistance;Pancreatology;2017-03
5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer;Cancer Letters;2015-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3